About Paradigm Neuroscience
.png/:/cr=t:0%25,l:0.39%25,w:99.22%25,h:99.22%25/rs=w:400,cg:true,m)
Joe Hulihan
...established Paradigm Neuroscience Consulting in March, 2015 to provide support for pharmaceutical development in the neurosciences. Dr. Hulihan has over 25 years of pharma experience in clinical trial strategy, development and execution.
Experience
Dr. Hulihan worked full-time in drug development consulting from 2015 through 2019. He then served as Chief Medical Officer for Marinus Pharmaceuticals until March 2025, where he focused on pediatric epilepsy and acute intervention for refractory status epilepticus. Previsouly, Dr. Hulihan worked in Medical Affairs and neuroscience pharmaceutical research at Johnson & Johnson (1999-2014) and has been involved in all phases of clinical drug development for neuropsychiatric therapies. These areas include epilepsy, migraine, schizophrenia, bipolar disorder, ADHD, and other neurologic and psychiatric disorders. Prior to joining Johnson & Johnson, he was Associate Professor of Neurology at Temple University School of Medicine, and Director of the EEG Laboratory and Clinical Neurophysiology fellowship program at Temple University Hospital.
Education
Dr. Hulihan graduated from Drexel University School of Medicine (formerly Hahnemann University) and completed a neurology residency at Hahnemann Hospital, both in Philadelphia. Following residency, he completed a clinical neurophysiology fellowship at Mayo Graduate School of Medicine and served as associate consultant in Neurology at Mayo Clinic in Rochester, Minnesota. In May, 2015 he received a Master of Science in Health Policy (MS-HP) from the Jefferson School of Population Health in Philadelphia.
Professional activities
He has published extensively in neurology and psychiatry journals, has presented at many scientific meetings, and has been active in professional societies for neurology, psychiatry and public health.